Peripheral Neuropathy and Haematopoietic stem-cell transplantation (HSCT): what the trial registry contains
The ClinicalTrials.gov registry holds 8 records for HSCT in Peripheral Neuropathy: 3 recruiting now, 1 labelled Phase 3 or 4, across 4 countries. Snapshot 2026-08-29.
Why this is studied in Peripheral Neuropathy
Peripheral neuropathy covers diabetic, chemotherapy-induced and idiopathic nerve damage with very different prognoses. Cell rationales target microvascular support and nerve regeneration, and unlike the central nervous system, peripheral nerves do regenerate — slowly, and only if the underlying cause is controlled.
What HSCT means in this table
Haematopoietic transplantation is the oldest and most consequential cell therapy in medicine, with conditioning regimens that carry real mortality risk alongside genuine disease-modifying power. Registrations under this label therefore mix decades-old standard-of-care protocols with newer autoimmune-reset trials, and the risk profile is nothing like that of an outpatient infusion.
The numbers
Every figure below comes from one reproducible query (peripheral neuropathy x hematopoietic stem cell transplantation) run against ClinicalTrials.gov API v2 on 2026-08-29.
| Metric | Value |
|---|---|
| Registered studies (all statuses) | 8 |
| Interventional studies in the sample | 8 |
| Recruiting right now | 3 |
| Completed | 2 |
| Terminated, withdrawn or suspended | 1 |
| Phase 3 or Phase 4 records | 1 |
| Countries with at least one site | 4 |
| Median planned enrolment | 61 participants |
| Largest single planned enrolment | 140 participants |
| First / most recent start year | 2005 — 2026 |
How mature is this evidence?
The ladder is partly climbed: 1 confirmatory-phase records against 8 in total, with the remainder concentrated in dose-finding and safety territory.
Completion status: 2 completed, 1 stopped early (12% of all records). A registration is a plan, not a result.
| Phase label | Records | Share |
|---|---|---|
| Phase 2 | 7 | 70% |
| Phase 3 | 1 | 10% |
| Phase 1 | 1 | 10% |
| Not applicable | 1 | 10% |
Median planned enrolment is 61 participants (largest single study: 140). Trials of this size can describe safety and generate hypotheses; detecting a modest clinical benefit reliably usually needs substantially larger numbers with a control group.
Where the studies are
Across 4 countries with registered sites, United States dominates at roughly 62% — a concentration driven by funding and regulation rather than by clinical outcome.
| Country | Studies with a site there |
|---|---|
| United States | 5 |
| Germany | 1 |
| China | 1 |
| Mexico | 1 |
Legal pathway differs by country — see where cell therapy is legal, by country.
Who runs them
Funding profile: 3 academic or hospital sponsors against 3 commercial ones — evenly split overall, which is worth knowing before reading any single positive report.
- Northwestern University — 1 record
- Franziskus-Krankenhaus — 1 record
- Masonic Cancer Center, University of Minnesota — 1 record
- M.D. Anderson Cancer Center — 1 record
- University of Florida — 1 record
- Fred Hutchinson Cancer Center — 1 record
Representative registered studies
Recruiting studies first, then the most advanced phases. Each identifier links to the registry record, where eligibility criteria, outcome measures and contacts are published.
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT06625190 — Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors | Phase 1, Phase 2 | Recruiting | 27 | University of Florida | 2026-02-11 |
| NCT07183761 — A Randomized Controlled Trial on the Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy in Subjects With Moderate to Severe Diabetic | Phase 2 | Recruiting | 140 | Min Long | 2025-10-01 |
| NCT05735717 — MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies | Phase 2 | Recruiting | 70 | Masonic Cancer Center, University of Minnesota | 2023-05-11 |
| NCT00716066 — Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases | Phase 2 | Active Not Recruiting | 53 | Fred Hutchinson Cancer Center | 2008-06 |
| NCT00434616 — Autologous Bone Marrow Stem Cell Transplantation for Critical, Limb-threatening Ischemia | Phase 2, Phase 3 | Unknown | 90 | Franziskus-Krankenhaus | 2007-04 |
| NCT04530487 — Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Ad | Phase 2 | Terminated | 1 | M.D. Anderson Cancer Center | 2020-08-19 |
| NCT00278629 — Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy | Phase 2 | Completed | 80 | Northwestern University | 2005-02-21 |
| NCT00730561 — Hematopoietic Stem Cell Transplantation for the Treatment of Limb Ischemia and Diabetic Neuropathy | n/a | Completed | 20 | Hospital Universitario Dr. Jose E. Gonzalez | 2006-03 |
What this page does and does not tell you
A registry is a plan repository. Counting entries tells you what people intended to study, which is a weaker thing than what they found.
If a clinic offers you this today, the useful question is not "is there research?" but "which of these registered studies is mine part of, and if none, what evidence applies to the exact product I am being sold?" The Provider Question Builder turns that into a scored checklist.
Frequently asked
How many HSCT studies for Peripheral Neuropathy are recruiting right now?
3 of 8 registered records were listed as recruiting in the 2026-08-29 snapshot. Recruitment status changes frequently; the registry record is authoritative.
Is HSCT an approved treatment for Peripheral Neuropathy?
Registration on ClinicalTrials.gov is not approval. Approval is granted by a regulator for a specific product and indication after review of submitted evidence. 8 registered studies tell you research exists, not that a product cleared review.
How advanced is the research on HSCT for Peripheral Neuropathy?
1 of 8 records carry a Phase 3 or Phase 4 label and 2 are marked completed. Registrations run from 2005 to 2026.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.
More on this condition
- Peripheral Neuropathy: cell-therapy evidence and registered trials
- How much does stem cell therapy for Peripheral Neuropathy cost? (2026)
- Peripheral Neuropathy stem cell therapy — your questions answered (2026)
- Peripheral Neuropathy: cell-therapy evidence by therapy class
- MSC vs PRP for Peripheral Neuropathy: what the registries show
Download the query data
Query totals are full API matches; status, phase and country counts describe the first up to 400 returned records per query. Query classes overlap and must not be summed as unique trials. Counts are not treatment outcomes. Snapshot: 2026-08-29. Methods and field definitions.